News

Setayeshpour, Y., Chen, SY., Dayanidhi, D.L. et al. Ascites protects against ferroptosis and enables the peritoneal growth of ovarian cancer. Nat Commun 17, 4190 (2026). https://doi.org/10.1038/s41467-026-72116-1 A newly published study in Nature Communications sheds light on an important question in ovarian cancer research: why ovarian cancer cells are often able to survive and spread throughout the abdominal cavity. Researchers from Duke University School of Medicine found

A new study from researchers, led by Dr. John Shen, at The University of Texas MD Anderson Cancer Center is helping doctors better understand how routine follow-up testing may improve care for people living with appendiceal cancer, a rare cancer that begins in the appendix. Researchers found that common blood tests known as tumor markers may help predict how patients respond to treatment and whether their cancer is more likely to return after surgery. The findings reinforce a

Falla-Zuniga, L.F., King, M.C., Pawlikowski, K. et al. Quality of Life After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC): Cancer Survivors’ Perspective Through In-Depth Interviews. Ann Surg Oncol 31, 7122–7132 (2024). What is this study about? This study looked at women with advanced ovarian cancer (stage III) who underwent: Cytoreductive surgery (surgery to remove as much cancer as possible) With or without HIPEC (heated chemotherapy deliv

Gudmundsdottir H, Yonkus JA, Thiels CA, Warner SG, Cleary SP, Kendrick ML, Truty MJ, Grotz TE. Oncologic Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Highly Selected Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol. 2023 Nov;30(12):7833-7839. doi: 10.1245/s10434-023-14138-3. Epub 2023 Aug 19. PMID: 37596449. What is this study about? This study looked at a challenging situation: pancreatic cancer that has spread

Darling A, Harlev C, O’Cearbhaill R . Use of hyperthermic intraperitoneal chemotherapy in the treatment of ovarian cancer: A multidisciplinary review. Surgical Oncology Insight, 2026; 3 What is this study about? This article looks at a treatment called HIPEC (Hyperthermic Intraperitoneal Chemotherapy). HIPEC is given during surgery for cancers that have spread inside the abdomen (like ovarian cancer). Doctors circulate warm chemotherapy directly in the belly to kill cancer

What is this interview about? This interview with Dr. Kiran Turaga explains a new approach to treating abdominal cancers called personalized chemotherapy. Instead of giving every patient the same treatment, doctors are working to match chemotherapy to each person’s specific tumor—so it works better and causes fewer side effects. Dr. Kiran Turaga Why is this important? Abdominal cancers (like colorectal, appendix, or ovarian cancers that spread in the abdomen) can be difficult

Falla-Zuniga LF, Sardi A, King MC, Lopez-Ramirez F, Kovalik V, Iugai S, Diaz-Montes T, Gushchin V. Small bowel obstruction and ovarian cancer: insights from a propensity-score matched study in patients with and without hyperthermic intraperitoneal chemotherapy after cytoreductive surgery. World J Surg Oncol. 2025 Aug 26;23(1):318. doi: 10.1186/s12957-025-03968-y. PMID: 40859247; PMCID: PMC12382003. What was this study about? People with advanced ovarian cancer sometimes devel

Ha, E., Suzuki, Y., Sarkaria, I.S. et al. Outcome Analysis of Cytoreductive Surgery and Hyperthermic Intrathoracic Chemoperfusion (HITHOC) for Pseudomyxoma Peritonei with Pleural Metastasis. Ann Surg Oncol 33, 3084–3090 (2026). https://doi.org/10.1245/s10434-025-18880-8 What is this study about? This study looked at a rare but challenging situation: when a condition called pseudomyxoma peritonei (PMP)—a cancer that usually starts in the abdomen—spreads to the chest (pleura).

Kovalik V, Sardi A, Falla-Zuniga LF, Wasti A, King MC, Iugai S, Uzhegova K, Nieroda C, Montes TD, Gushchin V. Patient-Reported Financial Toxicity of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Ann Surg Oncol. 2026 Mar 2. doi: 10.1245/s10434-025-19059-x. Epub ahead of print. PMID: 41772250 . What was this study about? This study looked at the financial challenges (often called “financial toxicity”) experienced by people undergoing cytoreductive surgery

Somashekhar, S.P. HIPEC in Advanced Ovarian Cancer: From Controversy to Contextual Standard of Care. Indian J Gynecol Oncolog 24 , 52 (2026). https://doi.org/10.1007/s40944-026-01122-4 What is this study about? This article looks at a treatment approach called HIPEC (hyperthermic intraperitoneal chemotherapy) for people with advanced ovarian cancer—a cancer that often spreads within the abdomen. Even with surgery and chemotherapy, many patients still have tiny cancer cells l

Al Mahrizi, A.D., Mossolem, F., Major, E. et al. Prophylactic Intraperitoneal Chemotherapy with Platinum Agents Following Curative Resection for Colorectal Cancer: A Systematic Review and Meta-Analysis. Ann Surg Oncol 33 , 2972–2984 (2026). https://doi.org/10.1245/s10434-025-18903-4 What is this study about? This research looked at a strategy to help prevent colorectal (colon and rectal) cancer from coming back after surgery. Even when surgery successfully removes all visib

A quarterly newsletter with the latest news, views and announcements from Peritoneal Surface Oncology Group International (PSOGI) Led by pioneering surgical oncologist Dr. Paul Sugarbaker, PSOGI is a collaboration of experts from around the world on the treatment of peritoneal cancer and is dedicated to improving treatment and survival of patients with peritoneal metastases . We are proud to share their quarterly newsletter. This newsletter highlights new research on cancers

Bhatt A, Stepanyan A, Al-Niaimi A et al. Principles of cytoreductive surgery for primary and metastatic peritoneal malignancies—the PSOGI–ESGO–ISSPP Lyon consensus. The Lancet Oncology, 27, e181-e194 Overview This article brings together an international group of experts to establish clear, consistent guidance on how to perform cytoreductive surgery, a complex procedure used to treat cancers that have spread within the abdominal lining (the peritoneum). These cancers can i

Xu N, Hasjim B, Rouhi A ... Validation of nomograms predicting survival in patients undergoing CRS-HIPEC for peritoneal dissemination of mucinous appendiceal cancer. Surgical Oncology Insight, 2026; 3 What is this study about? Some rare tumors that start in the appendix can spread inside the abdomen and produce a jelly-like substance. This condition is called pseudomyxoma peritonei (PMP). The main treatment for PMP is a major surgery called cytoreductive surgery (CRS) combin

Mouawad C, Osseis M, Pocard M. Beyond total PCI thresholds: Limitations of the surgical peritoneal cancer index in decision-making for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy . The American Journal of Surgery, 2026; 257 Rethinking how doctors decide who can get major cancer surgery This study looked at how doctors decide whether a patient with cancer that has spread inside the abdomen should have a complex surgery called CRS-HIPEC (a combination o

Rakchha Chhetri, Natansh D Modi, Bradley D Menz, Erik Cornelisse, David Postma, Nicole M Kuderer, Gary H Lyman, Sandra M Swain, Lee X Li, Ahmad Y Abuhelwa, Ross A McKinnon, Sina Vatandoust, Ganessan Kichenadasse, Andrew Rowland, Michael J Sorich, Ashley M Hopkins, Sex-based prognosis in industry-sponsored advanced solid tumour trials: an individual participant data meta-analysis of survival and adverse events, JNCI: Journal of the National Cancer Institute , 2026;, djag046,..

Sardi A, Uzhegova K, Iugai S, et al. Outcomes of cytoreductive surgery in unfavorable appendix cancer histologies: meaningful survival with complete cytoreduction despite high peritoneal cancer index. Presented at: Advanced Cancer Therapies; February 2026; Fort Lauderdale, FL . New Research Offers Hope for Patients with Advanced Appendix Cancer For patients diagnosed with rare and aggressive appendix cancers, treatment decisions can often feel limited—especially when the dis

Associations between the primary colorectal tumor budding score and the histological growth pattern of peritoneal metastases: A pilot study . Bouatrous, Mendhi et al. Surgical Oncology Insight, Volume 3, Issue 1, 100236 . About This Research Gastric (stomach) cancer that spreads to the lining of the abdomen—called peritoneal carcinomatosis—is one of the most difficult forms of the disease to treat. Traditional chemotherapy given through the bloodstream often struggles to re

Amblard I, Mercier F, Bartlett DL, Ahrendt SA, Lee KW, Zeh HJ, Levine EA, Baratti D, Deraco M, Piso P, Morris DL, Rau B, Tentes AAK, Tuech JJ, Quenet F, Akaishi E, Pocard M, Yonemura Y, Lorimier G, Delroeux D, Villeneuve L, Glehen O, Passot G; PSOGI and BIG RENAPE working groups. Cytoreductive surgery and HIPEC improve survival compared to palliative chemotherapy for biliary carcinoma with peritoneal metastasis: A multi-institutional cohort from PSOGI and BIG RENAPE groups.

In February, the Surgical Oncology team from Mercy Medical Center shared their research and clinical insights at the 20th Anniversary Advanced Cancer Therapies (ACT) Meeting — a landmark gathering for the peritoneal surface malignancy (PSM) community. Advancing Surgical Quality in CRS/HIPEC Care Dr. Vadim Gushchin, Alliance Board member, presented “The Power of Consistency in Achieving Surgical Quality: 30 Years, 2 Surgeons, 1 Nonacademic PSM Program.” This review highlighte